ALPMY
Price:
$11.69
Market Cap:
$3.19T
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are im...[Read more]
Industry
Drug Manufacturers - General
IPO Date
2009-12-29
Stock Exchange
PNK
Ticker
ALPMY
According to Astellas Pharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 55.67. This represents a change of -137.96% compared to the average of -146.65 of the last 4 quarters.
The mean historical PE Ratio of Astellas Pharma Inc. over the last ten years is 37.45. The current 55.67 PE Ratio has changed 14.76% with respect to the historical average. Over the past ten years (40 quarters), ALPMY's PE Ratio was at its highest in in the March 2020 quarter at 141.42. The PE Ratio was at its lowest in in the September 2023 quarter at -635.34.
Average
37.45
Median
23.17
Minimum
14.16
Maximum
171.82
Discovering the peaks and valleys of Astellas Pharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 394.47%
Maximum Annual PE Ratio = 171.82
Minimum Annual Increase = -47.99%
Minimum Annual PE Ratio = 14.16
Year | PE Ratio | Change |
---|---|---|
2024 | 171.82 | 394.47% |
2023 | 34.75 | 22.99% |
2022 | 28.25 | 7.36% |
2021 | 26.32 | 67.31% |
2020 | 15.73 | 6.37% |
2019 | 14.79 | -26.12% |
2018 | 20.02 | 41.41% |
2017 | 14.16 | -15.07% |
2016 | 16.67 | -47.99% |
2015 | 32.05 | 5.28% |
The current PE Ratio of Astellas Pharma Inc. (ALPMY) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
78.28
5-year avg
55.37
10-year avg
37.45
Astellas Pharma Inc.’s PE Ratio is greater than Bristol-Myers Squibb Company PFD CONV 2 (-251.63), less than Daiichi Sankyo Company, Limited (0), greater than AstraZeneca PLC (42.68), greater than Astellas Pharma Inc. (34.28), less than Bayer Aktiengesellschaft (175.09), greater than Otsuka Holdings Co., Ltd. (-4.81), greater than Pfizer Inc. (19.83), greater than Luye Pharma Group Ltd. (36.93), greater than Sanofi (9.80), greater than Amarin Corporation plc (15.42), greater than Novartis AG (-6.31), greater than null (12.63),
Company | PE Ratio | Market cap |
---|---|---|
-251.63 | $113.09B | |
0 | $63.61B | |
42.68 | $220.81B | |
34.28 | $19.92B | |
175.09 | $26.53B | |
-4.81 | $32.90B | |
19.83 | $157.31B | |
36.93 | $1.16B | |
9.80 | $132.76B | |
15.42 | $248.69M | |
-6.31 | $216.23B | |
12.63 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Astellas Pharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Astellas Pharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Astellas Pharma Inc.'s PE Ratio?
How is the PE Ratio calculated for Astellas Pharma Inc. (ALPMY)?
What is the highest PE Ratio for Astellas Pharma Inc. (ALPMY)?
What is the 3-year average PE Ratio for Astellas Pharma Inc. (ALPMY)?
What is the 5-year average PE Ratio for Astellas Pharma Inc. (ALPMY)?
How does the current PE Ratio for Astellas Pharma Inc. (ALPMY) compare to its historical average?